CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Nimodipine

尼莫地平 杂质对照品Nimodipine Impurities

EP35 个杂质条目35 impurity entries

本页汇总 尼莫地平 的 35 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 35 impurity reference standards of Nimodipine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 尼莫地平(Nimodipine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDeveloping and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology
    Journal of pharmaceutical and biomedical analysis · 2009 · Barmpalexis P et al.  ·  PMID 19369025  ·  DOI
  2. 杂质研究Impurity studiesDetermination of nimodipine in the presence of its degradation products and overall kinetics through a stability-indicating LC method
    Journal of chromatographic science · 2013 · Riekes MK et al.  ·  PMID 23118209  ·  DOI
  3. 杂质研究Impurity studiesMethodological assessment of the reduction of the content of impurities in nimodipine emulsion via the use of 21 amino acid protection
    International journal of nanomedicine · 2017 · Xie Y et al.  ·  PMID 28490879  ·  DOI
  4. 分析方法Analytical MethodsExploring novel electroanalytical approach using MWCNT nanostructures to quantify nimodipine
    Talanta · 2024 · Lema C et al.  ·  PMID 38043339  ·  DOI
  5. 分析方法Analytical MethodsEnantioselective assay of nimodipine in human plasma using liquid chromatography-tandem mass spectrometry
    Biomedical chromatography : BMC · 2021 · Isse FA et al.  ·  PMID 32840898  ·  DOI

尼莫地平 —— 原料药与杂质对照品Nimodipine — drug substance & impurities

共 36 个条目(含原料药本体)36 items incl. the drug substance
Nimodipine structure
EP原料药 APIAPI
尼莫地平Nimodipine
Nimodipine
CAS No.66085-59-4
Chemical FormulaC21H26N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 1 (Nimodipine EP Impurity A) structure
EPA
尼莫地平杂质1 (尼莫地平EP杂质A)Nimodipine Impurity 1 (Nimodipine EP Impurity A)
Nimodipine Impurity 1 (Nimodipine EP Impurity A)
CAS No.85677-93-6
Chemical FormulaC21H24N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 3 (Nimodipine EP Impurity C) structure
EPC
尼莫地平杂质3 (尼莫地平EP杂质C)Nimodipine Impurity 3 (Nimodipine EP Impurity C)
Nimodipine Impurity 3 (Nimodipine EP Impurity C)
CAS No.70172-96-2
Chemical FormulaC21H26N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 4 structure
4
尼莫地平杂质4Nimodipine Impurity 4
Nimodipine Impurity 4
CAS No.74936-69-9
Chemical FormulaC18H20N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 5 structure
5
尼莫地平杂质5Nimodipine Impurity 5
Nimodipine Impurity 5
CAS No.74936-76-8
Chemical FormulaC18H20N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 6 structure
6
尼莫地平杂质6Nimodipine Impurity 6
Nimodipine Impurity 6
CAS No.39562-21-5
Chemical FormulaC20H24N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 7 structure
7
尼莫地平杂质7Nimodipine Impurity 7
Nimodipine Impurity 7
CAS No.39562-75-9
Chemical FormulaC20H24N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 9 (C-Nitroso Nimodipine Impurity 66) structure
9
尼莫地平杂质9 (C-亚硝基尼莫地平杂质66)Nimodipine Impurity 9 (C-Nitroso Nimodipine Impurity 66)
Nimodipine Impurity 9 (C-Nitroso Nimodipine Impurity 66)
CAS No.1242511-97-2
Chemical FormulaC21H24N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 10 structure
10
尼莫地平杂质10Nimodipine Impurity 10
Nimodipine Impurity 10
CAS No.155861-24-8
Chemical FormulaC21H28N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 11 structure
11
尼莫地平杂质11Nimodipine Impurity 11
Nimodipine Impurity 11
CAS No.116799-92-9
Chemical FormulaC21H28N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 13 structure
13
尼莫地平杂质13Nimodipine Impurity 13
Nimodipine Impurity 13
CAS No.2200280-99-3
Chemical FormulaC21H26N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 14 structure
14
尼莫地平杂质14Nimodipine Impurity 14
Nimodipine Impurity 14
CAS No.1316606-40-2
Chemical FormulaC21H26N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 15 structure
15
尼莫地平杂质15Nimodipine Impurity 15
Nimodipine Impurity 15
CAS No.24871-74-7
Chemical FormulaC12H18O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 16 structure
16
尼莫地平杂质16Nimodipine Impurity 16
Nimodipine Impurity 16
CAS No.203740-59-4
Chemical FormulaC12H20N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 17 structure
17
尼莫地平杂质17Nimodipine Impurity 17
Nimodipine Impurity 17
CAS No.52326-05-3
Chemical FormulaC9H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 19 structure
19
尼莫地平杂质19Nimodipine Impurity 19
Nimodipine Impurity 19
CAS No.64163-94-6
Chemical FormulaC4H8N2O
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 22 structure
22
尼莫地平杂质22Nimodipine Impurity 22
Nimodipine Impurity 22
CAS No.40100-28-5
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 24 structure
24
尼莫地平杂质24Nimodipine Impurity 24
Nimodipine Impurity 24
CAS No.2334388-67-7
Chemical FormulaC21H27NO5
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 27 structure
27
尼莫地平杂质27Nimodipine Impurity 27
Nimodipine Impurity 27
CAS No.82219-48-5
Chemical FormulaC20H22N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 30 structure
30
尼莫地平杂质30Nimodipine Impurity 30
Nimodipine Impurity 30
CAS No.1369507-43-6
Chemical FormulaC22H28N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 33 structure
33
尼莫地平杂质33Nimodipine Impurity 33
Nimodipine Impurity 33
CAS No.82219-47-4
Chemical FormulaC20H24N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 35 structure
35
尼莫地平杂质35Nimodipine Impurity 35
Nimodipine Impurity 35
CAS No.464917-79-1
Chemical FormulaC11H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 36 (Mixture of E/Z-isomers) structure
36
尼莫地平杂质36 (混合E/Z构型)Nimodipine Impurity 36 (Mixture of E/Z-isomers)
Nimodipine Impurity 36 (Mixture of E/Z-isomers)
CAS No.14205-46-0
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 37 structure
37
尼莫地平杂质37Nimodipine Impurity 37
Nimodipine Impurity 37
CAS No.87966-40-3
Chemical FormulaC18H17ClN2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 38 structure
38
尼莫地平杂质38Nimodipine Impurity 38
Nimodipine Impurity 38
CAS No.122452-50-0
Chemical FormulaC17H16N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 39 structure
39
尼莫地平杂质39Nimodipine Impurity 39
Nimodipine Impurity 39
CAS No.85677-99-2
Chemical FormulaC17H14N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 40 structure
40
尼莫地平杂质40Nimodipine Impurity 40
Nimodipine Impurity 40
CAS No.663163-06-2
Chemical FormulaC21H24N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 49 structure
49
尼莫地平杂质49Nimodipine Impurity 49
Nimodipine Impurity 49
CAS No.51423-32-6
Chemical FormulaC15H16N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 50 structure
50
尼莫地平杂质50Nimodipine Impurity 50
Nimodipine Impurity 50
CAS No.85677-94-7
Chemical FormulaC18H18N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 51 structure
51
尼莫地平杂质51Nimodipine Impurity 51
Nimodipine Impurity 51
CAS No.88258-23-5
Chemical FormulaC18H18N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 52 structure
52
尼莫地平杂质52Nimodipine Impurity 52
Nimodipine Impurity 52
CAS No.88434-68-8
Chemical FormulaC15H12N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 55 structure
55
尼莫地平杂质55Nimodipine Impurity 55
Nimodipine Impurity 55
CAS No.85677-92-5
Chemical FormulaC14H15NO6
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 56 structure
56
尼莫地平杂质56Nimodipine Impurity 56
Nimodipine Impurity 56
CAS No.117177-77-2
Chemical FormulaC19H22N2O7
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 67 structure
67
尼莫地平杂质67Nimodipine Impurity 67
Nimodipine Impurity 67
CAS No.542-08-5
Chemical FormulaC7H12O3
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 68 structure
68
尼莫地平杂质68Nimodipine Impurity 68
Nimodipine Impurity 68
CAS No.459454-05-8
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nimodipine Impurity 69 structure
69
尼莫地平杂质69Nimodipine Impurity 69
Nimodipine Impurity 69
CAS No.1314966-13-6
Chemical FormulaC4H8N2O
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

尼莫地平 —— 研究文献与合成路线Nimodipine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 尼莫地平 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Nimodipine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Determination of nimodipine in the presence of its degradation products and overall kinetics through a stability-indicating LC method
    Riekes MK, Rauber GS, Kuminek G, et al. · Journal of chromatographic science · 2013 · 被引 6cited 6
  2. Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology
    Barmpalexis P, Kanaze FI, Georgarakis E · Journal of pharmaceutical and biomedical analysis · 2009 · 被引 15cited 15
  3. Methodological assessment of the reduction of the content of impurities in nimodipine emulsion via the use of 21 amino acid protection
    Xie Y, Zhuang Z, Zhang S, et al. · International journal of nanomedicine · 2017 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. Method for synthesizing nimodipine by cyclic compounds as solvents
    HUI LIU, ZHENYAN XU, SHA ZHANG · 公开号 CN101851192CN101851192 · 2010
  2. Nimodipine solid dispersoid and preparation method thereof
    XIUJUAN PANG, YINGJIE MA · 公开号 CN101474177CN101474177 · 2009
  3. (SBA-15)-nimodipine medicament and preparation method thereof
    HUI YU, QINGZHOU ZHAI · 公开号 CN101543493CN101543493 · 2009
  4. Nimodipine venous preparation and preparation method thereof
    YING AN · 公开号 CN101574317CN101574317 · 2009
  5. Nimodipine sustained release preparation and preparation method thereof
    PENG LIN · 公开号 CN101669944CN101669944 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

尼莫地平 杂质谱研究要点Nimodipine — impurity profiling notes

下面这些是拿到 尼莫地平 的 36 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 36 impurity entries for Nimodipine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances